MSLN and neoplasm: Early-phase trials targeting EGFR, MSLN (mesothelin), PSCA (prostate stem cell antigen), and MUC1 have shown preliminary evidence of tumor control, albeit with challenges related to trafficking and the immunosuppressive tumor microenvironment [149,150].